Please login to the form below

Not currently logged in
Email:
Password:

farletuzumab

This page shows the latest farletuzumab news and features for those working in and with pharma, biotech and healthcare.

Late-stage ovarian cancer

Late-stage ovarian cancer

Menarini Biotech's abagovomab and Morphotek/ Eisai's farletuzumab have both had disappointing results in late-stage clinical trials. ... Farletuzumab had also entered global phase III trials, in combination with carboplatin and a taxane, in patients with

Latest news

  • Eisai's farletuzumab fails ovarian cancer trial Eisai's farletuzumab fails ovarian cancer trial

    Farletuzumab has also been tipped as a long-term blockbuster prospect for Eisai, if it could be developed in multiple cancer indications. ... Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics